In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endotis Pharma

Latest From Endotis Pharma

Deals Shaping the Medical Industry (12/2009)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Charles Mentzer Prize awarded for antithrombotics pioneer

The French Society of Medicinal Chemistry has awarded its 2009 Charles Mentzer Prize to Dr Maurice Petitou.

Cardiovascular Cancer

Executive Briefing - Cardiovascular medicines: flogging pharma's dead horse?

Despite continuing pharmacological and physiological advances, ongoing public health campaigns, and well established guidelines defining challenging treatment targets, cardiovascular disease (CVD) kills more people globally than any other disease. Nevertheless, the pharmaceutical industry seems divided over whether CVD still holds the prospect of realising a reasonable return on investment. On the one hand, several companies are pulling out of CVD R&D, despite having a rich cardiovascular heritage. For example, Pfizer and Wyeth, currently mid-merger, individually announced a shift in focus away from cardiology towards areas such as oncology and neurology.

Metabolic Disorders Cardiovascular

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Endotis Pharma
  • Senior Management
  • Charles Woler, MD, Chmn. & CEO
    Maurice Petitou, PhD, Head, Preclinical R&D
    Eric Neuhart, MD, Head, Clinical R&D
    Stephane Degove, Head, Fin.
  • Contact Info
  • Endotis Pharma
    Phone: (33) 148 46 43 91
    Parc Biocitech , 102 route de Noisy
    Romainville, 93230